Teleflex acquires substantially all of BIOTRONIK Vascular Intervention business
The BIOTRONIK Vascular Intervention business, with the exception of IMDS products has been acquired by Teleflex, effective as of July 1st, 2025. These products are now part of the Teleflex portfolio. For questions or further information relating to the Vascular Intervention portfolio, please complete the contact form below.
Peripheral drug-coated balloons (DCBs) are minimally invasive angioplasty balloons coated in paclitaxel, an anti-proferative drug that is released up dilatation of the balloon within a peripheral artery to treat peripheral artery disease (PAD). Paclitaxel reduces the rate of restenosis and reinterventions, as shown in many clinical trials.
